Quantcast
Last updated on April 18, 2014 at 17:16 EDT

Latest Astellas Pharma Canada Inc. Stories

2013-04-10 08:31:06

Myrbetriq is now available in pharmacies across Canada MARKHAM, ON, April 10, 2013 /CNW/ - Overactive bladder (OAB) is a chronic, debilitating condition that can have a profound, negative impact on a patient's quality of life.( 1) Many patients with OAB are plagued by depression,(2) experience a disruption in sleep,(3) limit their social activity,(4) and experience a loss of control and decreased self-esteem.(5) An estimated 2.9 million Canadian men and women(6) suffer from OAB...

2013-03-08 08:23:03

MARKHAM, ON, March 8, 2013 /CNW/ - Astellas Pharma Canada, Inc., the Canadian subsidiary of Tokyo-based Astellas Pharma Inc., announced today Health Canada's approval of Myrbetriq(TM) (mirabegron, extended-release tablets). Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency.(1 )Mirabegron, a selective b3-adrenoceptor agonist, is a "first in class" therapeutic agent with a mechanism of action...

2012-03-28 02:25:15

Partnership establishes grant to advance urology research in Canada MARKHAM, ON, March 28, 2012 /PRNewswire/ - The Canadian Urological Association (CUA) and Astellas Pharma Canada, Inc. have announced the creation of a research alliance aimed at advancing research and patient care in the field of urology. Astellas Pharma Canada has pledged $750,000 over a period of five years to support Canadian investigators in urology. The objective of the CUA Astellas Research Grant Program is to...